| Identification | Back Directory | [Name]
NELFINAVIR | [CAS]
159989-64-7 | [Synonyms]
AG 1341
nefinavir
NELFINAVIR
NELFINAVIR-12
8a-beta))-a-bet
NELFINAVIR USP/EP/BP
Nelfinavir Regeoisomer
AG 1341; AG-1341; AG1341
Nelfinavir & Nelfinavir Mesylate
3-isoquinolinecarboxamide,n-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hy
(3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide
N-tert-butyl-2-[2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)- | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C32H45N3O4S | [MDL Number]
MFCD01938163 | [MOL File]
159989-64-7.mol | [Molecular Weight]
567.78 |
| Chemical Properties | Back Directory | [Melting point ]
185-186 °C | [alpha ]
D -119.23° (c = 0.26 in methanol) | [Boiling point ]
786.8±60.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
≥ 20.45mg/mL in Ethanol | [form ]
Powder | [pka]
pKa1 6.0; pKa2 11.06(at 25℃) | [color ]
White to off-white | [Water Solubility ]
7g/L(temperature not stated) |
| Hazard Information | Back Directory | [Uses]
Antiviral. | [Definition]
ChEBI: An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. | [Indications]
Nelfinavir (Viracept) is probably the most commonly
used protease inhibitor because of its low incidence of
serious adverse effects. Its most common side effects
are diarrhea and flatulence; these may resolve with continued
use. In addition to the drugs contraindicated for
use with all protease inhibitors, amiodarone, rifampin,
and quinidine are contraindicated in patients taking
nelfinavir. | [Brand name]
Viracept (Agouron). | [Antimicrobial activity]
Nelfinavir inhibits HIV-1 and HIV-2 proteases. Bioavailability
is affected to only a limited degree by combination with lowdose
ritonavir. | [Acquired resistance]
Resistance is most frequently selected through a D30N mutation
in the HIV protease. An L90M mutation also confers
resistance. | [Pharmaceutical Applications]
A synthetic chemical formulated as the mesylate for oral
administration. | [Pharmacokinetics]
Oral absorption: c. 70–80% (with food)
Cmax 750 mg thrice daily: c. 3–4 mg/L
1250 mg twice daily: c. 4 mg/L
Cmin 750 mg thrice daily: c. 1–3 mg/L
1250 mg twice daily: c. 0.7–2.2 mg/L
Plasma half-life: c. 3.5 h
Volume of distribution: c. 2–7 L/kg
Plasma protein binding: >98%
Absorption and distribution
Food improves the bioavailability and the drug should be administered with a light meal. The semen:plasma ratio is 0.07. It is distributed into breast milk.
Metabolism and excretion
One major and several minor oxidative metabolites are found in plasma. Most of an oral dose is recovered in feces as unchanged drug (22%) and metabolites (78%). The remainder is recovered in urine, mainly unchanged.
An increase in the area under the time–concentration curve (AUC) has been observed in patients with hepatic impairment, but specific dose recommendations have not been made. | [Clinical Use]
Treatment of HIV infection (in combination with other antiretroviral drugs) | [Side effects]
The most common adverse effect is diarrhea of mild
to moderate severity. Other side effects include nausea,
fatigue, vomiting and headache. It is associated with less
dyslipidemia in comparison with ritonavir-boosted protease
inhibitors. | [Metabolism]
Following oral administration, nelfinavir peak levels in plasma ranged from 0.34 mg/mL (10 mg/kg in the dog) to 1.7 mg/mL (50 mg/kg in the rat). In the dog, nelfinavir was slowly absorbed, and bioavailability was 47%. The drug appeared to be metabolized in the liver, and the major excretory route was in feces. |
|
|